Results 41 to 50 of about 221,594 (183)

Vaccination of risk groups in England using the 13 valent pneumococcal conjugate vaccine: economic analysis. [PDF]

, 2012
OBJECTIVE: To estimate the cost effectiveness of vaccinating people with high risk conditions against invasive pneumococcal disease using the 13 valent pneumococcal conjugate vaccine.
Edmunds, W. John, van Hoek, Albert Jan, Trotter, Caroline L, Rozenbaum, Mark H., C. L. Trotter, Miller, Elizabeth, Rozenbaum, Mark H, D. Fleming, Trotter, Caroline L., E. Miller, M. H. Rozenbaum, Edmunds, W John, W. J. Edmunds, Fleming, Douglas, A. J. van Hoek   +14 more
core   +2 more sources

Cost-Effectiveness of 20-Valent Pneumococcal Conjugate Vaccine Among US Children with Underlying Medical Conditions

Infectious Diseases and Therapy
Introduction A 20-valent pneumococcal conjugate vaccine (PCV20) was recently recommended for use among US children. We evaluated the cost-effectiveness of PCV20 among children aged 6 years with chronic medical conditions (CMC+) and children aged 6 years ...
Mark H. Rozenbaum, Erica Chilson, Raymond Farkouh, Liping Huang, Alejandro Cane, Adriano Arguedas, Maria J. Tort, Vincenza Snow, Ahuva Averin, Derek Weycker, Dhwani Hariharan, Mark Atwood   +11 more
doaj   +1 more source

Refractory Eczema as a Presenting Feature of Common Variable Immunodeficiency

JEADV Clinical Practice, EarlyView.
ABSTRACT Common variable immunodeficiency (CVID) is the most prevalent symptomatic inborn error of immunity (IEI) in adults. It presents with recurrent infections and non‐infectious complications, including autoimmunity, lymphoproliferation and dermatitis.
Mercedes Sanchez‐Diaz, Lars Matthies, Andrea Vanegas Ramirez   +2 more
wiley   +1 more source

Continued control of pneumococcal disease in the UK - the impact of vaccination

, 2011
Streptococcus pneumoniae, also known as the pneumococcus, is an important cause of morbidity and mortality in the developed and developing world. Pneumococcal conjugate vaccines were first introduced for routine use in the USA in 2000, although the seven-
Gladstone, R.A., Jefferies, J.M., Gladstone, R.A, S. N. Faust, Faust, S.N, Faust, S.N ., R. A. Gladstone, Clarke, S.C., J. M. Jefferies, Jefferies, J.M, Clarke, S.C, S. C. Clarke   +11 more
core   +1 more source

Infection risk in rheumatoid arthritis patients treated with biologic and targeted therapies

Rheumatology &Autoimmunity, EarlyView.
In this context, infections associated with each biologic and targeted drug are summarized to inform the stratification of RA patients, including the characteristics of the susceptible patients and their concomitant therapy. We aim to provide a benefit‐risk analysis for clinical decision, and vital indications for the prevention of highly correlated ...
Lujing Wang, Jieshi Lin, Jie Qian
wiley   +1 more source

IgE‐Binding Bacterial Components Not Yet Documented in the Allergen Databases and Their Allergenic Mechanisms: An EAACI Position Paper

Allergy, EarlyView.
ABSTRACT Among bacteria that are associated with the development and/or exacerbation of allergic/atopic diseases, several have been described to produce IgE‐binding components. However, only one bacterial protein, Bac s 1, is currently listed in the official database of the World Health Organization/International Union of Immunological Societies (WHO ...
Uta Jappe, Marua Abu Risha, Ioana Agache, Claus Bachert, Barbara Bröker, Riccardo Castagnoli, Gabriele Gadermaier, Richard E. Goodman, Amir Guemari, Christiane Hilger, Alain Jacquet, Sabine Kespohl, Ludger Klimek, Annette Kuehn, Jonas Lidholm, Vera Mahler, Markus Ollert, Thomas A. Platts‐Mills, Monika Raulf, Peter Schmid‐Grendelmeier, Frieder Schmiedeke, Marianne van Hage, Joana Vitte, Josefina Zakzuk, Anna Pomés   +24 more
wiley   +1 more source

Analysis of pneumococcal vaccination status and its influencing factors among young and middle-aged populations: an online survey

Zhongguo gonggong weisheng
ObjectiveTo understand the pneumococcal vaccination status and its influencing factors among young and middle-aged populations, and provide reference for promoting pneumococcal vaccination.
Ziying CHEN, Sijia ZHOU, Xin JIANG, Wen LIU, Yuhang MA, Kai WANG, Zhixiang DAI, Shuhan TANG, Chengxi ZHENG, Jianli HU, Zhihang PENG   +10 more
doaj   +1 more source

Serotype-Independent Protection Against Invasive Pneumococcal Infections Conferred by Live Vaccine With lgt Deletion

Frontiers in Immunology, 2019
Streptococcus pneumoniae is the most common respiratory bacterial pathogen among cases of community-acquired infection in young children, older adults, and individuals with underlying medical conditions.
A-Yeung Jang, A-Yeung Jang, Ki Bum Ahn, Yong Zhi, Yong Zhi, Hyun-Jung Ji, Hyun-Jung Ji, Jing Zhang, Seung Hyun Han, Huichen Guo, Sangyong Lim, Sangyong Lim, Joon Yong Song, Jae Hyang Lim, Ho Seong Seo, Ho Seong Seo   +15 more
doaj   +1 more source

Pneumococcal Immunization Strategies for High-Risk Pediatric Populations Worldwide: One Size Does Not Fit All

Vaccines, 2021
Despite the significant reduction in pneumococcal disease due to pneumococcal vaccines, protection of vulnerable high-risk individuals, especially pediatric populations, remains a great challenge.
Theano Lagousi, Ioanna Papadatou, Petros Strempas, Elena Chatzikalil, Vana Spoulou   +4 more
doaj   +1 more source

Long‐Term Outcomes After Elective Splenectomy for Haematological Disease: A 27‐Year Single‐Centre Study

ANZ Journal of Surgery, EarlyView.
Splenectomy is a safe and effective treatment option in selected patients with haematological disease, despite declining referrals over the last 27 years in the era of targeted therapies. Outcomes are favourable when performed laparoscopically and long‐term follow‐up demonstrates sustained haematologic benefit in surviving patients.
Salil Dutt Barrett, Anthony Downhill, Douglas Greer, William Stevenson, Ian Kerridge, Chris Ward, Matthew Greenwood, Naomi Mackinlay, Luke Coyle, Thomas J. Hugh   +9 more
wiley   +1 more source